Suspension of trading
Bellicum Pharmaceuticals, Inc. Stock
Stocks
BPXA
US0794814048
Biotechnology & Medical Research
OTC Markets Traded|
Delayed
Börse Stuttgart
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-2.31% | -53.99% |
| Market Cap | 1.76M 1.55M 1.47M 1.33M 2.5M 169M 2.51M 17.57M 6.79M 86.45M 6.63M 6.48M 278M | P/E 2021 |
-1.77x | P/E 2022 | -0.89x |
|---|---|---|---|---|---|
| Enterprise Value | -20.07M -17.65M -16.69M -15.14M -28.44M -1.93B -28.6M -200M -77.19M -983M -75.36M -73.73M -3.16B | EV / Sales 2021 |
-5.43x | EV / Sales 2022 | -10.4x |
| Free-Float |
98.45% | Yield 2021 * |
-
| Yield 2022 | - |
| 3 years | 0 |  | 0.19 |
| 5 years | 0 | | 0.19 |
| 10 years | 0 | | 0.19 |
| Manager | Title | Age | Since |
|---|---|---|---|
Dave Maggio
CEO | Chief Executive Officer | 66 | 23/02/2024 |
Richard Fair
CEO | Chief Executive Officer | 57 | 31/01/2017 |
| Director | Title | Age | Since |
|---|---|---|---|
Richard Fair
BRD | Director/Board Member | 57 | - |
Judith Kilmovsky
BRD | Director/Board Member | - | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 22/11/23 | Baker Bros. Advisors LP
| Option | Company | 4,232,698 | 44.5721% | |
| 03/01/23 | Exercice | Director | 60,414 | 0.7014% | ||
| 03/01/23 | Exercice | Director | 60,414 | 0.7014% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -2.31% | - | - | 822K | |
| -0.37% | -3.67% | +57.21% | +87.75% | 71.81B | |
| +1.26% | -0.02% | +39.92% | +85.67% | 60.06B | |
| +0.19% | +1.61% | +35.10% | +17.20% | 27.93B | |
| -0.14% | -2.75% | -14.13% | +356.79% | 25.7B | |
| +0.57% | +1.10% | +1.02% | -2.89% | 24.89B | |
| +0.74% | +1.80% | +26.64% | -7.50% | 20.92B | |
| -1.70% | +0.43% | +150.24% | +323.16% | 15.04B | |
| +0.36% | +2.01% | +49.51% | +160.70% | 14.46B | |
| +3.91% | -3.51% | -4.56% | +517.49% | 13.87B | |
| Average | +0.48% | -1.60% | +37.88% | +170.93% | 27.47B | |
| Weighted average by Cap. | +0.42% | -1.91% | +38.66% | +128.25% |
| 2021 | 2022 | |
|---|---|---|
| Net sales | 6.2M 5.45M 5.16M 4.68M 8.78M 595M 8.83M 61.74M 23.84M 304M 23.28M 22.77M 976M | 1.5M 1.32M 1.25M 1.13M 2.13M 144M 2.14M 14.94M 5.77M 73.47M 5.63M 5.51M 236M |
| Net income | -9.7M -8.54M -8.07M -7.32M -13.75M -932M -13.83M -96.64M -37.32M -475M -36.44M -35.65M -1.53B | -24.97M -21.96M -20.77M -18.84M -35.38M -2.4B -35.58M -249M -96.04M -1.22B -93.76M -91.73M -3.93B |
| Net Debt | -46.16M -40.59M -38.39M -34.82M -65.39M -4.43B -65.77M -460M -178M -2.26B -173M -170M -7.27B | -21.84M -19.21M -18.16M -16.47M -30.94M -2.1B -31.12M -217M -83.98M -1.07B -81.98M -80.21M -3.44B |
Employees
13
- Stock Market
- Stocks
- BPXA Stock
Select your edition
All financial news and data tailored to specific country editions
